肝胆相照论坛

标题: HBV Journal Reveiw[Nov] Tenofovir Effective in Treating Patients with Entecavir [打印本页]

作者: StephenW 时间: 2011-11-4 08:18 标题: HBV Journal Reveiw[Nov] Tenofovir Effective in Treating Patients with Entecavir

本帖最后由 StephenW 于 2011-11-4 08:18 编辑

Tenofovir Effective in Treating Patients with Entecavir Resistance[poor response]

               While entecavir and tenofovir are considered the best  available antivirals and are recommended as first-treatment options, 3% of  patients treated with entecavir don’t respond to treatment.
               Researchers tried treating 14 of the patients who had  not responded to entecavir with tenofovir to see if that drug would be  effective in these patients. The patients were Chinese, predominantly male,  HBeAg-positive, and infected with either genotype C (71%) or B (29%).
               After 65 weeks of treatment with tenofovir, all 14 patients  achieved undetectable HBV-DNA and normal ALT levels. Two of 12 HBeAg-positive  lost HBeAg and developed “e” antibodies over 80 weeks of treatment. None of the  tenofovir-treated patients failed to respond to treatment.
               “In conclusion,” researchers wrote in the Journal of Viral Hepatitis, “suboptimal response to entecavir is rare  (approximately3%). Tenofovir is safe and very effective in the management of  HBV patients with (poor response) to entecavir.”

作者: StephenW 时间: 2011-11-4 08:20

泰诺福韦治疗用恩替卡韦抵抗患者（反应不佳）
有效

虽然恩替卡韦和替诺福韦被认为是最好的抗病毒药物和建议作为第一治疗方案，用恩替卡韦治疗的患者的3％不响应处理。

研究人员试图治疗的患者没有回应恩替卡韦，替诺福韦看到，如果这种药物会可以有效地在这些患者中14。中国，以男性为主，HBeAg阳性的患者和感染或者C型（71％）或B（29％）。

替诺福韦治疗65周后，所有14例患者，取得了检测不到HBV- DNA和ALT正常水平。两个12 HBeAg阳性失去HBeAg和开发的“E”抗体超过80周的治疗。没有替诺福韦治疗的患者未能响应处理。

“总之，”研究人员写道：在病毒性肝炎杂志“，”恩替卡韦是最理想的反应罕见（approximately3％）。泰诺福韦是安全的和非常有效的乙肝患者的管理（反应不佳），恩替卡韦的。“

作者: zhanggui 时间: 2011-11-14 19:21

净是胡说八道。。。

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)